1. Jemal A, Murray T, Ward E et al. Cancer statistics 2005. CA Cancer J Clin 2005; 55(1): 10-30.
2. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finastcridc on the development of prostate cancer. N Engl J Med 2003; 349(3): 215-224.
3. Steers WU. 5a1pha-reductase activity in the prostate. Urology 2001; 58(6 Suppl 1): 17-24.
4. Andriole G, Bruchovsky N, Chung LW et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172(4 Pt 1):1399-1403.
5. Walsh PC, Madden JD, Harrod MJ et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in psendovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291(18): 944-949.
6. Iniperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002; 198(1-2): 51-59.
7. Imperato-McGinley J, Gautier T, Zirinsky K et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1992; 75(4): 1022-1026.
8. Wilson JD, Roehrbom C. Long-term consequences of castration in men lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman coints. J Clin Endocrinol Metab 1999; 84(12): 4324-4331.
9. Wu AH, Whittemore AS, Kolonel LN et al. Serum androgens and sex hormonebinding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidcmiol Biomarkers Prev 1995; 4(7): 735-741.
10. Hsing AW, Tsao L. Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85(1): 60-67.
11. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. Journal of the National Cancer Institute 1996; 88(16): 1118-1126.
12. Stattin P, Lumtne S, Tenkancn L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004; 108(3): 418-424.
13. Chen C, Weiss NS, Stanczyk FZ et al. Endogenous sex hormones and prostate cancer risk a case control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003; 12(12): 1410-1416.
14. Kaaks R, Lukanova A, Rinaldi S et al. Interrelationships between plasma testosterone, SHBG, IGF-1, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12(4): 309-315.
15. Heikkila R, Aho K, Heliovaara M et al. Scrum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma; a longitudinal study. Cancer 1999; 86(2): 312-315.
16. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999; 80(7): 930-934.
17. Anonymous. Physician‘s Dcsk Reference. 60th ed. Montvale. NJ: Thompson PDR 2006.
18. Rittrnaster RS. Finasteride. N Engl J Med 1994; 330(2):120-125.
19. Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother 1995; 49(7-8): 319-324.
20. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350(5): 482-492.
21. Foley CL, Kirby RS. 5 alpha-reductase inhibitors: what‘s new? Curr Opin Urol 2003; 13(1): 31-37.
22. Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71(6): 1552-1555.
23. McConnell JD, Wilson JD, George FW et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74(3): 505-508.
24. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng1 J Med 1992; 327(17): 1185-1191.
25. Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci 2003; 74(2): 393-406.
26. Prahalada S, Tarantal AF, Harris GS et al. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology 1997; 55(2): 119-131.
27. Clark RL, Antonello JM, Grossman SJ et al. External genitalia abnormalities in male rats exposed in utero to finasteridc, a 5 alpha-reductase inhibitor. Teratology 1990; 42(1): 91-100.
28. Wessells H, Roy J, Bannow J et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61(3): 579-84.
29. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N EngI J Med 2003; 349(25): 2387-2398.
30. Rhoden EL, Gobbi D, Menti E, Rhoden C, Teloken C. Effects of the chronic use of finasteride on testicular weight and spermatogenesis in Wistar rats. BJU Int 2002; 89(9): 961-963.
31. Cukierski MA, Sina JL, Prahalada S et al. Decreased fertility in male rats administered the 5 alpha-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation. Reprod Toxicol 1991; 5(4): 353-362.
32. Wise LD, Minsker DH, Cukicrski MA et al. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5 alpha-reductase inhibitor. Reprod Toxicol 1991; 5(4): 337-346.
33. Iguer-Ouada M, Verstegen JP. Effect of finasteride (Prosear MSD) on seminal composition, prostate function and fertility in male dogs. J Reprod Fertil Suppl 1997; 51:139-149.
34. De Marzo AM, Meeker AK, Zha S et al. Human prostate cancer precursors and pathobiology. Urology 2003; 62(5 Suppl I): 55-62.
35. Marks LS, Partin AW, Dorey FJ et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999; 53(3): 574-580.
36. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996; 81(2): 814-819.
37. Rochrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63(4): 709-715.
38. Pannek J, Marks LS, Pearson JD et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998; 159(2): 449-453.
39. Oesterling JE, Roy J. Agha A et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer, effects of finasteride. The Finasteride PSA Study Group. Urology 1997; 50(1): 13-18.
40. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997; 57(4): 714-719.
41. Etzioni RD, Howlader N, Shaw PA et al. Long-term effects of finasteride on prostate specific antigen levels; results from the prostate cancer prevention trial. J Urol 2005; 174(3): 877-881.
42. Feigl P, Blurnenstein B. Thompson I et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995; 16(3): 150-163.
43. Unger JM, LeBlanc M, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urol Oncol 2004; 22(4): 362-368.
44. Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 2005; 23(9): 1911-1920.
45. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implichtions and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005; 118(8): 850-857.
46. Makridakis NM, Reichardt JK. Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. J Urol 2004; 171(2 Pt 2): S25-8; discussion S8-9.
47. Makridakis NM, Ross RK, Pike MC et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999; 354(9183): 975-978.
48. Jaffe JM, Malkowicz SB, Walker AH et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000; 60(6): 1626-1630.
49. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type 11. Phannacngenetics 2000; 10(5): 407-413.
50. Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172(4 Pt 1): 1314-1317.
51. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Mod 2004; 350(22): 2239-2246.
52. Kulkartti GS, Al-Azab R, Lockwood G et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006; 175: 505-509.
53. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91: 608-612.
54. Heinonen OP, Albums D, Virtamo J et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Nat Cancer Inst 1998; 90: 440-446.
55. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate canter in the transgenic adcnocarcinoma of mouse prostate model. Cancer Res 2002; 62: 1370-1376.
56. Price D, Stein B, Sieber P et al. Toremifene for the prevention of prostare cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase DB clinical trial. J Urol 2006; 176; 965-970.
57. Xu Y, Dalrymple S, Becker R, Isaacs JT. Pharmacologic basis for dutasteride‘s enhanced efficacy against prostatic cancers. Clin Cancer Res 2006; 12: 4072-4079.
58. Giovannucci E. A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med 2002; 227: 852.
59. Kirsh VA, Mayne ST, Peters U et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 92.
60. Severson RK, Nomura AM, Grove JS et al. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989; 49: 1857.
61. Hebert JR, Hurley TG, Olendzid BC et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Nat Cancer Inst 1998; 90: 1637.
62. Yu L, Blackburn GL, Zhou JR. Genistein and daidzein downrcgulate prostate androgen-regulated transcript-1 (PART-1) gene expression induced by dihydrotestosterone in human prostate LNCaP cancer cells. J Nutr 2003; 133: 389.
63. Santibanez JF, Navarro A, Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res 1997; 17: 1199.
64. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10: 1307.
65. Konery BR, Johnson CS, Trump DL et al. Vitamin D in the prevention and treatment of prostate cancer. Semin Urol 1999; 17: 77.
66. Giovannucci E, Liu Y, Rimm EB et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Nat Cancer Inst 2006; 98: 451.
67. Khan MA, Partin AW. Vitamin D for the management of prostate cancer. Rev Urol 2004; 6: 95.
68. Kolonel LN, Nomura AM, Hinds MW el al. Role of diet in cancer incidence in Hawaii. Cancer Res 1983; 43: 2397.
69. Hayes RB, Ziegler RG, Gridley G et al. Dietary Electors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 25.
70. Brawley OW. The potential for prostate cancer chemoprevention. Rev Urol 2000; 4(Suppl 5): S11.
71. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in canter prevention: a critical review ofnon-selective COX-2 blockade. Oncol Rep 2005; 13: 559.
72. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chernoprovention. J Urol 2004; 171: S59.
73. Andrews J, Djakiew D, Krygier S et al. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol; 2000; 50: 277.
74. Chan JM, Feraco A, Shuman M et al. The epidemiology of prostate cancer with a focus on nonsteroidal anti-inflammatory drugs. Hematology. Hematol Oncol Clin North Am 2006; 20: 797.
75. Eresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 35: 1092.